183 related articles for article (PubMed ID: 31646908)
1. Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience.
Del Forno S; Degli Esposti E; Salucci P; Leonardi D; Iodice R; Arena A; Raimondo D; Paradisi R; Seracchioli R
Gynecol Endocrinol; 2020 May; 36(5):445-447. PubMed ID: 31646908
[TBL] [Abstract][Full Text] [Related]
2. Which is the destiny of ulipristal acetate for uterine fibroids? A commentary on the Italian medicines agency (AIFA) pronouncements.
Indraccolo U; Conzadori S; Greco P
Recenti Prog Med; 2019 Feb; 110(2):98-99. PubMed ID: 30843536
[TBL] [Abstract][Full Text] [Related]
3. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
4. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
5. Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program.
Donnez J; Arriagada P; Marciniak M; Larrey D
Expert Opin Drug Saf; 2018 Dec; 17(12):1225-1232. PubMed ID: 30460871
[TBL] [Abstract][Full Text] [Related]
6. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
7. Role of ethnicity in treating uterine fibroids with ulipristal acetate.
Murji A; Crosier R; Chow T; Ye XY; Shirreff L
Fertil Steril; 2016 Oct; 106(5):1165-1169. PubMed ID: 27336213
[TBL] [Abstract][Full Text] [Related]
8. Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up.
Nicolás I; Martínez-Zamora MÁ; Gracia M; Carrion A; Feixas G; Bernal L; Quintas L; Rius M; Castelo-Branco C; Carmona F
Gynecol Endocrinol; 2021 Sep; 37(9):831-835. PubMed ID: 34044726
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
10. Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study.
Giarrè G; Franchini M; Castellacci E; Malune ME; Di Spiezio Sardo A; Saccone G; Angioni S
Gynecol Endocrinol; 2020 Feb; 36(2):171-174. PubMed ID: 31392917
[TBL] [Abstract][Full Text] [Related]
11. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
12. An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids.
Kang S; Brinker A; Jones SC; Dimick-Santos L; Avigan MI
Drug Saf; 2020 Dec; 43(12):1267-1276. PubMed ID: 32647996
[TBL] [Abstract][Full Text] [Related]
13. Ulipristal acetate on quality of life and sexual function of women with uterine fibromatosis.
Biscione A; Barra V; Bellone E; Severi FM; Luisi S
Gynecol Endocrinol; 2020 Jan; 36(1):87-92. PubMed ID: 31328597
[TBL] [Abstract][Full Text] [Related]
14. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
15. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
16. What does non-eligibility for myoma surgery mean in the context of sequential prescription of ulipristal acetate?
Pourcelot AG; Capmas P; Laberge P; Fernandez H
J Gynecol Obstet Hum Reprod; 2020 Apr; 49(4):101688. PubMed ID: 31972353
[TBL] [Abstract][Full Text] [Related]
17. Long-term medical management of uterine fibroids with ulipristal acetate.
Donnez J; Donnez O; Matule D; Ahrendt HJ; Hudecek R; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Loumaye E
Fertil Steril; 2016 Jan; 105(1):165-173.e4. PubMed ID: 26477496
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-term intermittent pharmacological therapy with ulipristal acetate on reducing the volume of uterine fibroids and relieving symptoms.
Kyeong HK; Choi J; Na YJ; Kim HG
Minerva Obstet Gynecol; 2023 Jun; 75(3):236-242. PubMed ID: 36786781
[TBL] [Abstract][Full Text] [Related]
19. Medical Therapy for Fibroids: What Next for Ulipristal Acetate?
Ekanem E; Talaulikar V
Adv Ther; 2021 Jan; 38(1):137-148. PubMed ID: 33201387
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.
Donnez J; Hudecek R; Donnez O; Matule D; Arhendt HJ; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Terrill P; Osterloh I; Loumaye E
Fertil Steril; 2015 Feb; 103(2):519-27.e3. PubMed ID: 25542821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
